International Journal of Trend in Scientific Research and Development (IJTSRD)
Volume 8 Issue 4, Jul-Aug 2024 Available Online: www.ijtsrd.com e-ISSN: 2456 – 6470

# Pharmacovigilance in Post-Marketing Studies: Ensuring Long-Term Safety Monitoring

**Ziyauddin Sayyed[1], Rachel Wilson J[2], G Naveen Goud[3], Chidireddy Devi Divya[4]**

[1,3,4]B. Pharmacy, Student at ClinoSol Research, Hyderabad, Telangana, India
[2]MSC, Child Health, Student at ClinoSol Research, Hyderabad, Telangana, India

## ABSTRACT
Pharmacovigilance in post-marketing studies is critical for ensuring the long-term safety and efficacy of pharmaceutical products after they have been released to the market. While clinical trials provide initial insights into a drug's safety and effectiveness, post-marketing surveillance plays a crucial role in identifying adverse drug reactions (ADRs) and long-term effects that may not become apparent until a drug is used by a broader, more diverse patient population. This abstract explores the importance of pharmacovigilance in post-marketing studies, emphasizing the methodologies used to monitor drug safety, including spontaneous reporting systems, electronic health records, and active surveillance programs. It also addresses the challenges faced in this field, such as underreporting of ADRs, data integration issues, and the need for robust regulatory frameworks to manage and respond to safety signals. The role of modern technologies, including artificial intelligence and big data analytics, in enhancing pharmacovigilance efforts is also discussed. By ensuring rigorous and continuous safety monitoring, pharmacovigilance helps to mitigate risks, improve patient outcomes, and contribute to the overall efficacy of public health interventions. The ongoing evolution of pharmacovigilance practices is essential for adapting to new safety challenges and maintaining high standards of drug safety throughout the lifecycle of medicinal products.

***KEYWORDS:*** *Pharmacovigilance, Post-Marketing Surveillance, Adverse Drug Reactions, Long-Term Safety Monitoring, Electronic Health Records, Active Surveillance, Data Integration, Artificial Intelligence, Big Data Analytics, Drug Safety*

***How to cite this paper:*** Ziyauddin Sayyed | Rachel Wilson J | G Naveen Goud | Chidireddy Devi Divya "Pharmacovigilance in Post-Marketing Studies: Ensuring Long-Term Safety Monitoring" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-8 | Issue-4, August 2024, pp.995-1001, URL: www.ijtsrd.com/papers/ijtsrd67271.pdf

IJTSRD67271



## INTRODUCTION
Pharmacovigilance, the science and activities dedicated to the detection, assessment, understanding, and prevention of adverse effects or any drug-related problems, is a critical aspect of drug safety management that becomes increasingly vital once a pharmaceutical product is released to the market. While clinical trials play a fundamental role in assessing the initial safety and efficacy of new medications, they have inherent limitations that often necessitate ongoing surveillance once the drug is in widespread use. These trials are conducted under highly controlled conditions with a relatively homogeneous patient population, which means they may not fully capture the full spectrum of potential adverse drug reactions (ADRs) and other issues that could arise when a drug is exposed to the general population. Clinical trials typically involve smaller sample sizes and shorter durations compared to the vast and varied real-world settings in which medications are ultimately used. As a result, some rare or long-term adverse effects may not become apparent until the drug is used by a much larger and more diverse group of patients, each with their own unique health profiles, comorbidities, and interactions with other medications.

Post-marketing pharmacovigilance is designed to address these gaps by providing a framework for continuous safety monitoring and evaluation once a drug is on the market. This ongoing surveillance is crucial for identifying and managing risks that were not evident during the pre-market phase. In the post-marketing phase, a drug's safety profile is continually assessed through a variety of methods, including spontaneous reporting systems, active surveillance programs, and the analysis of electronic health records (EHRs). Spontaneous reporting systems, such as the FDA's Adverse Event Reporting System (FAERS) and the European Medicines Agency's (EMA) EudraVigilance, rely on reports from healthcare professionals and patients about adverse effects experienced with a particular drug. These reports are essential for detecting potential safety signals and generating hypotheses about the drug's safety profile. However, the effectiveness of these systems can be hampered by underreporting and variability in the quality of the submitted data.

Active surveillance programs offer a more systematic approach to monitoring drug safety. These programs involve the proactive collection and analysis of data from large cohorts of patients or through registries specifically established to track the long-term safety and effectiveness of medications. For instance, programs like the Sentinel Initiative in the U.S. and various registries in Europe are designed to identify safety issues by analyzing real-world data and conducting targeted studies. These programs can provide valuable insights into how drugs perform in broader, more heterogeneous patient populations, including those with multiple health conditions and those taking multiple medications.

The integration of electronic health records (EHRs) into pharmacovigilance efforts represents another significant advancement. EHRs provide a wealth of information about patients' medical histories, including their medication use, comorbidities, and treatment outcomes. By analyzing data from EHRs, researchers and regulatory bodies can gain a more comprehensive understanding of the potential risks associated with a drug and identify patterns that may indicate emerging safety concerns. This approach facilitates real-time monitoring and can help detect issues that may not be apparent through spontaneous reporting alone.

Pharmacovigilance also involves the use of advanced statistical methods and data mining techniques to identify safety signals from large datasets. Techniques such as disproportionality analysis, which compares the frequency of reported adverse events for a specific drug to the frequency for other drugs, can help detect potential safety issues. Bayesian statistical methods and machine learning algorithms are increasingly being used to enhance signal detection and risk assessment, enabling more sophisticated analyses of complex data.

Despite its critical role, pharmacovigilance faces several challenges that can impact its effectiveness. One major challenge is the issue of underreporting, where healthcare professionals and patients may not report adverse effects due to lack of awareness, perceived lack of severity, or other reasons. This can result in an incomplete understanding of a drug's safety profile and delay the identification of important safety issues. Additionally, integrating data from various sources, such as spontaneous reports, EHRs, and active surveillance programs, can be complex and challenging due to discrepancies in data quality and format.

Regulatory and ethical issues also play a significant role in pharmacovigilance. Ensuring compliance with diverse regulatory requirements across different countries while protecting patient privacy and confidentiality is a delicate balance. International collaboration and standardization of pharmacovigilance practices are essential for addressing these challenges and improving the effectiveness of safety monitoring systems. Furthermore, the application of advanced technologies, such as artificial intelligence and big data analytics, holds promise for enhancing pharmacovigilance efforts, but these technologies also bring their own set of challenges, including the need for high-quality data and the potential for algorithmic biases.

## Methodologies in Post-Marketing Pharmacovigilance

### 1. Spontaneous Reporting Systems:

Spontaneous reporting systems are a fundamental component of pharmacovigilance, serving as a primary mechanism for the ongoing monitoring of drug safety once medications are on the market. These systems rely on the voluntary submission of reports about adverse drug reactions (ADRs) from healthcare professionals and patients, which are then compiled into national and international databases. The primary goal of spontaneous reporting is to identify and assess safety signals that might not have been detected during pre-market clinical trials due to their limited size, duration, and controlled conditions. By capturing real-world data from a broader and more diverse population, spontaneous reporting systems play a critical role in uncovering potential safety issues and enhancing our understanding of a drug's risk-benefit profile.

Healthcare professionals, including doctors, pharmacists, and nurses, are often the primary reporters in these systems. They are typically well-positioned to recognize and report ADRs based on their clinical expertise and direct observations of patients' reactions to medications. Patients themselves are also encouraged to report ADRs, which can provide additional insights into drug safety from the user's perspective. The information collected includes details about the drug involved, the nature and timing of the adverse event, patient demographics, and other relevant clinical data. This wealth of information is crucial for detecting patterns that might indicate emerging safety concerns or previously unrecognized risks. National databases, such as the FDA's Adverse Event Reporting System (FAERS) in the United States, and the European Medicines Agency's (EMA) EudraVigilance system in Europe, are central repositories for these reports. FAERS and EudraVigilance compile reports from various sources, including spontaneous submissions, and make them available for analysis. These databases are instrumental in monitoring the safety of drugs on a large scale, providing valuable data that can lead to the identification of new safety signals or the confirmation of previously suspected issues. The process of signal detection begins with the collection of ADR reports, which are then subjected to statistical analysis to identify any disproportionate frequencies of adverse events associated with specific drugs. Disproportionality analysis, a common method used in spontaneous reporting systems, compares the frequency of reported adverse events for a particular drug with the frequency of those events for other drugs. This approach helps to identify whether the occurrence of certain adverse events is higher than would be expected by chance. For instance, if a particular drug is associated with a higher than expected number of reports of a rare side effect, this may indicate a potential safety issue that warrants further investigation.

One of the strengths of spontaneous reporting systems is their ability to detect rare and unexpected ADRs that may not be captured in clinical trials due to their relatively small sample sizes. These systems provide a mechanism for identifying potential safety concerns that emerge only after a drug is used by a larger, more diverse population over an extended period. For example, some serious ADRs may only become apparent when a drug is used by individuals with multiple comorbidities or who are taking other medications, conditions that are often not fully represented in clinical trials. Despite their crucial role, spontaneous reporting systems have limitations that can impact their effectiveness. Underreporting is a significant challenge, as not all ADRs are reported to these systems. Healthcare professionals and patients may fail to report adverse events due to various factors, including lack of awareness, perceived lack of severity, or the belief that reporting is unnecessary. This can result in incomplete data and potentially delay the identification of safety issues. Efforts to improve reporting rates, such as increased education and awareness campaigns, are essential for enhancing the reliability of spontaneous reporting systems. Another challenge is the quality and completeness of the reports submitted. Inaccurate or incomplete data can complicate the analysis and interpretation of safety signals. Ensuring that reports provide detailed and accurate information is crucial for effective signal detection and risk assessment. Training and guidelines for reporters can help improve the quality of submissions and ensure that the data collected is useful for safety monitoring. Additionally, the analysis of data from spontaneous reporting systems can be complex and requires sophisticated statistical methods to identify and evaluate safety signals. Data mining techniques, such as disproportionality analysis and Bayesian statistics, are used to analyze large volumes of reports and detect potential safety issues. However, these methods are not without limitations and can sometimes lead to false positives or misinterpretations. It is essential to validate and corroborate potential signals with additional data, such as clinical trial results or real-world evidence, before making definitive conclusions about drug safety. The role of spontaneous reporting systems in pharmacovigilance is complemented by other methods of safety monitoring, such as active surveillance programs and the analysis of electronic health records (EHRs). While spontaneous reporting systems provide valuable data, they are most effective when used in conjunction with other sources of information. For example, active surveillance programs can systematically monitor drug safety through cohort studies and registries, providing a more comprehensive view of a drug's safety profile. EHRs offer detailed patient data that can enhance the analysis of ADRs and help identify patterns or trends that may not be evident from spontaneous reports alone.

**2. Electronic Health Records (EHRs):**

The integration of Electronic Health Records (EHRs) into pharmacovigilance represents a significant advancement in the field of drug safety monitoring, offering a range of benefits that enhance the ability to collect, analyze, and interpret real-time data. EHRs, which are digital versions of patients' medical histories maintained by healthcare providers, encompass a broad array of information including medication history, comorbidities, treatment outcomes, and demographic details. This comprehensive repository of patient data provides a valuable resource for identifying patterns of adverse drug reactions (ADRs) and assessing long-term effects of medications, significantly expanding the scope and effectiveness of pharmacovigilance efforts. One of the key advantages of integrating EHRs into pharmacovigilance is the ability to access and analyze data in real-time. Traditional pharmacovigilance methods, such as spontaneous reporting systems, often rely on periodic updates and can suffer from delays in data collection and analysis. In contrast, EHRs enable continuous monitoring of patient information, allowing for the immediate identification of potential safety signals and the rapid assessment of emerging risks. This real-time capability is particularly crucial for detecting and responding to rare or unexpected ADRs that may only become apparent when a drug is used by a large and diverse population over time. EHRs provide a comprehensive view of patient health, capturing detailed information on medication usage, including dosage, duration, and adherence. This information is essential for understanding the context in which ADRs occur and for identifying potential contributing factors. For instance, by analyzing EHR data, researchers can determine whether an ADR is associated with specific drug formulations, interactions with other medications, or underlying health conditions. This level of detail allows for more nuanced insights into drug safety and can help pinpoint the root causes of adverse events. Furthermore, the integration of EHRs into pharmacovigilance facilitates the analysis of large-scale datasets, enabling researchers to identify patterns and trends that might not be evident from smaller, isolated reports. The vast amount of data available through EHRs can be subjected to advanced analytical techniques, such as machine learning algorithms and big data analytics, to uncover correlations and predict potential safety issues. For example, algorithms can analyze EHR data to detect clusters of ADRs associated with specific drugs, leading to the identification of safety signals that might prompt further investigation or regulatory action. The comprehensive nature of EHRs also allows for the assessment of long-term effects of medications, which is a critical aspect of pharmacovigilance. While clinical trials provide initial data on the short-term safety and efficacy of drugs, they often do not capture the long-term risks and benefits that may emerge over extended periods of use. By examining longitudinal data from EHRs, researchers can track patients' health outcomes over time, providing insights into chronic side effects, delayed adverse reactions, and the overall impact of a drug on long-term health. This information is invaluable for updating safety profiles and making informed decisions about drug use and regulatory actions.

**3. Active Surveillance Programs:**

Active surveillance represents a proactive approach in pharmacovigilance, systematically monitoring drug safety through the use of cohort studies, registries, and continuous data collection, aiming to provide a more comprehensive and real-time assessment of drug-related risks beyond what is captured through spontaneous reporting systems. Unlike passive methods that rely on voluntary reporting of adverse drug reactions (ADRs), active surveillance involves the deliberate and structured collection of data from large, diverse populations, which helps in identifying safety issues that may not emerge until a drug is used extensively in the general population. This method allows for a more detailed and nuanced understanding of a drug's safety profile, addressing limitations inherent in traditional pharmacovigilance practices and providing crucial information to regulators, healthcare providers, and patients. Cohort studies are a fundamental component of active surveillance, where groups of patients who are exposed to a specific drug are followed over time to monitor for adverse effects. These studies often involve comparing the health outcomes of patients receiving the drug of interest with those receiving alternative treatments or no treatment at all. By tracking and analyzing health outcomes in a controlled and systematic manner, cohort studies can provide valuable insights into the long-term safety and efficacy of medications, helping to identify rare or delayed ADRs that may not be apparent in smaller clinical trials. This method also allows for the assessment of potential interactions with other medications and underlying health conditions, offering a more comprehensive view of a drug's risk profile. Registries are another key tool in active surveillance, functioning as specialized databases that collect and maintain detailed information on patients receiving specific drugs or treatments. Registries can be disease-specific, drug-specific, or population-based, and they play a crucial role in monitoring the safety and effectiveness of medications in real-world settings. For example, drug-specific registries may track patients taking a particular medication to gather data on its long-term effects, while disease-specific registries may focus on the safety of treatments for particular conditions. These registries facilitate the collection of structured data, enabling ongoing evaluation and analysis of drug safety across diverse patient populations. Additionally, registries can support post-marketing studies by providing data that helps validate safety signals detected through other methods, such as spontaneous reporting.

Programs such as the Sentinel Initiative in the United States and the European Union's Pharmacovigilance System (PhV) exemplify the application of active surveillance on a larger scale. The Sentinel Initiative, launched by the U.S. Food and Drug Administration (FDA), represents a groundbreaking effort to enhance drug safety monitoring through a large-scale, national electronic health data network. The initiative leverages data from a variety of sources, including electronic health records, insurance claims, and patient registries, to conduct active surveillance and risk assessment. By analyzing data from millions of patients, the Sentinel Initiative aims to identify potential safety issues more efficiently and accurately, providing timely information that can inform regulatory decisions and public health interventions. Similarly, the European Union's Pharmacovigilance System (PhV) employs active surveillance methods to monitor drug safety across member states. The PhV system integrates data from multiple national pharmacovigilance centers and databases, allowing for a comprehensive assessment of drug safety throughout the EU. This system uses a range of active surveillance tools, including cohort studies and registries, to track the safety of medications in diverse populations. By pooling data from various sources and countries, the PhV system enhances the ability to detect safety signals and evaluate risks in a more extensive and representative manner. Active surveillance offers several advantages over traditional pharmacovigilance methods. One of the primary benefits is its ability to provide real-time data and early detection of safety issues. By continuously monitoring drug safety through cohort studies and registries, active surveillance programs can identify emerging risks and address them promptly, potentially preventing adverse effects before they become widespread. This proactive approach helps ensure that safety concerns are managed effectively and that regulatory actions are based on the most current and comprehensive data available.

**4. Signal Detection and Risk Assessment:**

Signal detection and risk assessment are critical components of pharmacovigilance that leverage advanced statistical methods and data mining techniques to identify and evaluate potential safety signals from extensive datasets. These sophisticated analytical approaches are essential for discerning patterns and correlations within vast amounts of data, which can then be used to uncover previously unrecognized adverse drug reactions (ADRs) and assess their potential impact on patient safety. One of the primary techniques employed in signal detection is disproportionality analysis, which examines the frequency of specific ADRs associated with a particular drug in comparison to the overall frequency of those ADRs across all drugs in a database. This method involves calculating ratios such as the Reporting Odds Ratio (ROR) or the Proportional Reporting Ratio (PRR) to identify whether the occurrence of an ADR is disproportionately higher for a given drug compared to others. For example, if a drug is associated with a significantly higher number of reports of a rare side effect than would be expected based on the overall reporting rates, this may indicate a potential safety signal that warrants further investigation. Disproportionality analysis is particularly valuable for detecting rare or unexpected ADRs that might not be evident through traditional reporting methods, as it highlights cases where the association between a drug and an ADR deviates significantly from what is anticipated. Bayesian statistics offer another powerful tool for signal detection, providing a probabilistic approach to evaluating the likelihood that a particular drug is associated with an ADR. Bayesian methods use prior knowledge and historical data to update the probability of an ADR occurring with a specific drug based on new evidence. This approach allows for a more nuanced assessment of safety signals, as it incorporates both existing data and new findings to refine the understanding of drug-related risks. Bayesian models can adjust for various factors, such as patient demographics and concomitant medications, which helps to reduce the potential for false positives and improves the accuracy of signal detection. Data mining techniques further enhance the ability to identify safety signals by applying algorithms and computational methods to large, complex datasets. These techniques include machine learning and artificial intelligence, which can analyze patterns and correlations across extensive data sources, such as electronic health records, insurance claims, and spontaneous reporting systems. Machine learning algorithms, for example, can be trained to recognize patterns in data that might indicate an ADR, enabling the detection of subtle and previously unnoticed associations. These methods can also adapt and improve over time as more data becomes available, enhancing their predictive accuracy and sensitivity. The integration of data mining techniques with traditional signal detection methods provides a more comprehensive approach to pharmacovigilance, allowing for the identification of safety signals with greater precision and efficiency. Advanced statistical methods and data mining techniques play a crucial role in risk assessment by enabling the evaluation of the severity and potential impact of identified safety signals. Once a potential ADR is detected, further analysis is required to determine its clinical significance and relevance to patient safety. This involves assessing factors such as the frequency and severity of the ADR, the strength of the association with the drug, and the potential for causality. Risk assessment also includes evaluating the potential impact on public health, considering factors such as the size of the patient population exposed to the drug and the availability of alternative treatments. Collaboration between regulatory agencies, healthcare providers, and pharmaceutical companies is essential for effective signal detection and risk assessment. Regulatory agencies, such as the FDA and EMA, utilize these techniques to monitor drug safety and make informed decisions about labeling, warnings, and regulatory actions. Healthcare providers contribute by reporting adverse events and providing clinical context that aids in the interpretation of safety signals. Pharmaceutical companies play a role in conducting further studies and providing additional data to support the evaluation of safety signals. Despite their advantages, advanced statistical methods and data mining techniques are not without limitations. Disproportionality analysis can sometimes lead to false positives or false negatives, especially if the reporting database is incomplete or biased. Bayesian methods require accurate prior information and assumptions, which can affect the reliability of the results if not appropriately calibrated. Data mining techniques, while powerful, can also be susceptible to overfitting and the inclusion of irrelevant variables, which can impact the accuracy of signal detection. Addressing these limitations involves continuous refinement of methods, validation with external data, and a careful interpretation of results. In conclusion, signal detection and risk assessment are integral to pharmacovigilance, with advanced statistical methods and data mining techniques providing the tools necessary to identify and evaluate potential safety signals from large datasets. Disproportionality analysis and Bayesian statistics offer valuable approaches for detecting and assessing ADRs, while data mining techniques enhance the ability to analyze complex datasets and uncover subtle associations. Despite challenges, the application of these methods contributes to a more effective and comprehensive understanding of drug safety, ultimately leading to better risk management and enhanced patient protection

## Challenges in Post-Marketing Pharmacovigilance

***Underreporting***: One of the major challenges in pharmacovigilance is the underreporting of ADRs. Many ADRs go unreported due to a lack of awareness among healthcare professionals and patients, or due to the perception that the reported adverse events are not severe.

***Data Integration:*** Integrating data from various sources, such as spontaneous reports, EHRs, and insurance claims, can be complex. Discrepancies between data sources and the challenge of harmonizing diverse datasets can impede effective safety monitoring.

***Regulatory and Ethical Issues:*** Ensuring compliance with regulatory requirements while protecting patient privacy is a critical issue. Regulations vary across countries, and there is a need for international harmonization of pharmacovigilance practices.

***Technological Limitations:*** Although AI and machine learning offer promising advancements, their application in pharmacovigilance requires high-quality data and careful validation. Overreliance on these technologies without adequate oversight may lead to erroneous conclusions.

## Advancements and Future Directions

***Artificial Intelligence and Big Data Analytics:*** The use of AI and machine learning algorithms in pharmacovigilance is growing. These technologies can enhance signal detection, predict potential ADRs, and automate data analysis processes. Big data analytics allows for the integration of large, diverse datasets, providing more comprehensive safety evaluations.

***Patient-Centric Approaches***: Increasing patient involvement in pharmacovigilance through digital health tools, mobile apps, and patient-reported outcomes can improve ADR reporting rates and provide valuable insights into drug safety.

***Global Collaboration***: Strengthening international collaboration and data sharing among regulatory agencies, healthcare providers, and pharmaceutical companies is crucial for a more effective global pharmacovigilance system. Collaborative efforts can lead to the development of standardized practices and improved safety monitoring.

## Conclusion

Pharmacovigilance in post-marketing studies is essential for ensuring the long-term safety of pharmaceutical products. Despite the challenges, advancements in technology and data analysis hold the promise of enhancing pharmacovigilance efforts. Ongoing research and development are needed to address technical, ethical, and practical challenges, ensuring that pharmacovigilance practices evolve to meet the demands of modern healthcare. By continuously improving pharmacovigilance methodologies and fostering global cooperation, the pharmaceutical industry can better protect public health and ensure the safe use of medications throughout their lifecycle.

**References:**


[1] Dunbar CE, High KA, Joung JK, Kohn DB, Ozawa K, Sadelain M. Gene therapy comes of age. Science. 2018;359(6372) https://doi.org/10.1126/science.aan4672.

[2] Cavero I, Seimetz D, Koziel D, Zimmermann W-H, Holzgrefe HH. 19th Annual meeting of the safety pharmacology society: regulatory and safety perspectives for advanced therapy medicinal products (cellular and gene therapy products). Expert Opin Drug Saf. 2020;19(5):553–8. https://doi.org/10.1080/14740338.2020.1741546.

[3] O'Leary MC, Lu X, Huang Y, Lin X, Mahmood I, Przepiorka D, et al. FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Clin Cancer Res. 2019;25(4):1142–6. https://doi.org/10.1158/1078-0432.CCR-18-2035.

[4] Day RO, Williams KM. Open-label extension studies. Drug Saf. 2007;30(2):93–105. https://doi.org/10.2165/00002018-200730020-00001.

[5] Richardson A, Apaydin E, Baxi S, Vockley J, Akinniranye O, Ross R, et al. Landscape review and evidence map of gene therapy, part II: chimeric antigen receptor-T cell (CAR-T), autologous cell, antisense, RNA interference (RNAi), zinc finger nuclease (ZFN), genetically modified oncolytic herpes virus. 2019. https://www.pcori.org/sites/default/files/PCORI-Emerging-Technologies-Therapeutics-ReportLandscape-Review-Evidence-Map-Gene-Therapy-Part-II.pdf. Accessed 2 Oct 2020.

[6] Cho MK. Open-label extension studies: are they really research? Am J Bioethics. 2014;14(4):60–1. https://doi.org/10.1080/15265161.2014.889958.

[7] Anguela XM, High KA. Entering the modern era of gene therapy. Annu Rev Med. 2019;70:273–88. https://doi.org/10.1146/annurev-med-012017-043332.

[8] Darrow JJ, Avorn J, Kesselheim AS. FDA approval and regulation of pharmaceuticals, 1983–2018. J Am Med Assoc. 2020;323(2):164–76. https://doi.org/10.1001/jama.2019.20288.